Showing results (191-200 of 225) with videos related to

Sort By:
Pageof 23
European Urology|March 23, 2024
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 StudyRoberto Iacovelli, Chiara Ciccarese, Sebastiano Buti, et al.
The Lancet. Oncology|September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 studyKarim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
Clinical Genitourinary Cancer|April 14, 2024
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry StudyVeronica Mollica, Francesco Massari, Marco Maruzzo, et al.
The Journal of Urology|November 30, 2014
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinomaRoberto Iacovelli, Alessio Farcomeni, Cora N Sternberg, et al.
Frontiers in Oncology|August 14, 2023
U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenarioSergio Bracarda, Roberto Iacovelli, Valentina Baldazzi, et al.
Journal for Immunotherapy of Cancer|January 21, 2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter studyPaolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, et al.
Clinical Genitourinary Cancer|August 1, 2020
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective StudyMaria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, et al.
Clinical & Experimental Metastasis|February 16, 2024
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinationsMichele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, et al.
The Lancet. Oncology|March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trialThomas Powles, Toni K Choueiri, Laurence Albiges, et al.
Cancers|March 14, 2026
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future DirectionsMaria Chiara Sighinolfi, Giuseppe Pallotta, Marzia Del Re, et al.
Pageof 23